 Home > Active Ingredient News > Drugs Articles > Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally

Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

high quality tweezers

triple negative cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 11, 2021, AnchorDx and Twist Bioscience announced that they have jointly developed a methylated library preparation and targeted enrichment NGS sequencing product for pan-cancer species research-Extension Vista-benchmark methylated pan-cancer detection (hereinafter referred to as "methylated pan-cancer detection product") was launched globally on September 24 (US time)
.

This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.
It has the advantages of wider coverage, more accurate data analysis, and higher detection efficiency.
It combines the long-term independent accumulation of large samples of benchmark medical The proven advantages of pan-cancer biomarkers, as well as Twist's technical advantages and quality control advantages in probe design, DNA synthesis, can ensure stable and uniform high performance in large-scale screening applications
.

The product covers 47 TCGA (The Cancer Genome Atlas) disease types, including 31 types of cancers such as lung cancer, breast cancer, and colorectal cancer.

Reference materials:

[1] The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally

11-05

Related Products

N-Methyl-L-alanine3913-67-5

CAS No.: 3913-67-5

Industrial Grade

$1-1.04/KG FOB

High Purity 99% PEG MGF CAS 108174-48-7 Customized Peptides from China OUDA

CAS No.: 108174-48-7

Pharmacy Grade

$2-2.6/G FOB

Wholesales Purity 99 Peptides Powder Sema Tirz Retatrutide 5mg/10mg/15mg to Door From China

CAS No.: 2023788-19-2

Pharmacy Grade

$150-180/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally

Related Articles

The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally